Market Cap
US$5.0b
Last Updated
2019/11/20 23:36 UTC
Data Sources
Company Financials +
Executive Summary
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Snowflake
Fundamentals
Flawless balance sheet and good value.
Similar Companies
Share Price & News
How has Exelixis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXEL's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0.7%
EXEL
2.5%
US Biotechs
0.9%
US Market
1 Year Return
-8.9%
EXEL
10.8%
US Biotechs
16.8%
US Market
Return vs Industry: EXEL underperformed the US Biotechs industry which returned 10.8% over the past year.
Return vs Market: EXEL underperformed the US Market which returned 16.8% over the past year.
Shareholder returns
| EXEL | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.7% | 2.5% | 0.9% |
| 30 Day | -2.0% | 11.8% | 4.5% |
| 90 Day | -20.0% | 7.6% | 6.2% |
| 1 Year | -8.9%-8.9% | 11.8%10.8% | 19.4%16.8% |
| 3 Year | 0%0% | 18.6%14.8% | 47.5%38.0% |
| 5 Year | 836.9%836.9% | 5.8%0.8% | 62.0%44.1% |
Price Volatility Vs. Market
How volatile is Exelixis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
How Much Are Exelixis, Inc. (NASDAQ:EXEL) Insiders Taking Off The Table?2 weeks ago | Simply Wall St
Results: Exelixis, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts2 weeks ago | Simply Wall St
Are Investors Undervaluing Exelixis, Inc. (NASDAQ:EXEL) By 29%?Valuation
Is Exelixis undervalued compared to its fair value and its price relative to the market?
31.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXEL ($16.49) is trading below our estimate of fair value ($23.9)
Significantly Below Fair Value: EXEL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: EXEL is good value based on its PE Ratio (8.1x) compared to the Biotechs industry average (17.5x).
PE vs Market: EXEL is good value based on its PE Ratio (8.1x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: EXEL is good value based on its PEG Ratio (0.5x)
Price to Book Ratio
PB vs Industry: EXEL is overvalued based on its PB Ratio (3.1x) compared to the US Biotechs industry average (2.9x).
Next Steps
Future Growth
How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
16.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXEL's forecast earnings growth (16.4% per year) is above the savings rate (2.7%).
Earnings vs Market: EXEL's earnings (16.4% per year) are forecast to grow faster than the US market (14.4% per year).
High Growth Earnings: EXEL's earnings are forecast to grow, but not significantly.
Revenue vs Market: EXEL's revenue (13.2% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: EXEL's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (18.8%).
Next Steps
Past Performance
How has Exelixis performed over the past 5 years?
74.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXEL has a high level of non-cash earnings.
Growing Profit Margin: EXEL's current net profit margins (64%) are higher than last year (49.4%).
Past Earnings Growth Analysis
Earnings Trend: EXEL has become profitable over the past 5 years, growing earnings by 74.3% per year.
Accelerating Growth: EXEL's earnings growth over the past year (66.2%) is below its 5-year average (74.3% per year).
Earnings vs Industry: EXEL earnings growth over the past year (66.2%) underperformed the Biotechs industry 86.5%.
Return on Equity
High ROE: EXEL's Return on Equity (38.2%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Exelixis's financial position?
Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($972.1M) exceeds its short term liabilities ($141.1M)
Long Term Liabilities: EXEL's short term assets ($972.1M) exceeds its long term liabilities (40.1M)
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: EXEL has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if EXEL's debt is covered by short term assets.
Next Steps
Dividend
What is Exelixis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Exelixis's salary, the management and board of directors tenure and is there insider trading?
4.3yrs
Average management tenure
CEO
Michael Morrissey (58yo)
9.3yrs
Tenure
US$7,977,535
Compensation
Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. sin ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD7.98M) is about average for companies of similar size in the US market ($USD6.77M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.3yrs
Average Tenure
58yo
Average Age
Experienced Management: EXEL's management team is considered experienced (4.3 years average tenure).
Board Age and Tenure
17.1yrs
Average Tenure
65.5yo
Average Age
Experienced Board: EXEL's board of directors are seasoned and experienced ( 17.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 50,000 |
| Max Price | US$20.36 |
| Entity | Individual |
| Role | Chief Financial Officer Executive VP & CFO |
| Shares | 36,261 |
| Max Price | US$20.70 |
| Entity | Individual |
| Shares | 4,272 |
| Max Price | US$22.27 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 248,180 |
| Max Price | US$22.41 |
| Entity | Individual |
| Role | Chief Legal Officer Executive VP |
| Shares | 14,818 |
| Max Price | US$19.91 |
| Entity | Individual |
| Role | Chief Financial Officer Executive VP & CFO |
| Shares | 8,791 |
| Max Price | US$19.70 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Gisela Schwab (62yo)
President of Product Development & Medical Affairs and Chief Medical Officer
- Tenure: 13.8yrs
- Compensation: US$3.60m
Stelios Papadopoulos (71yo)
Co-Founder & Chairman
- Tenure: 21.8yrs
- Compensation: US$421.05k
Michael Morrissey (58yo)
CEO, President & Director
- Tenure: 9.3yrs
- Compensation: US$7.98m
Peter Lamb (58yo)
Executive VP of Scientific Strategy & Chief Scientific Officer
- Tenure: 12.8yrs
- Compensation: US$3.17m
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations
- Tenure: 2.9yrs
Jeffrey Hessekiel (50yo)
Executive VP
- Tenure: 5.8yrs
- Compensation: US$2.73m
Chris Senner (51yo)
Executive VP & CFO
- Tenure: 4.3yrs
- Compensation: US$3.39m
Jon Berndt
Vice President of Sales
- Tenure: 4.2yrs
Gregg Bernier
Vice President of Marketing
- Tenure: 4.2yrs
Dana Aftab
Executive Vice President of Business Operations
- Tenure: 3.8yrs
Board Members
Jack Wyszomierski (63yo)
Independent Director
- Tenure: 15.8yrs
- Compensation: US$406.05k
Charlie Cohen (68yo)
Independent Director
- Tenure: 24yrs
- Compensation: US$408.70k
Stelios Papadopoulos (71yo)
Co-Founder & Chairman
- Tenure: 21.8yrs
- Compensation: US$421.05k
Michael Morrissey (58yo)
CEO, President & Director
- Tenure: 9.3yrs
- Compensation: US$7.98m
George Poste (75yo)
Independent Director
- Tenure: 15.3yrs
- Compensation: US$396.05k
Lance Willsey (57yo)
Independent Director
- Tenure: 22.6yrs
- Compensation: US$384.70k
George Scangos (71yo)
Independent Director
- Tenure: 23.1yrs
- Compensation: US$375.70k
Vincent Marchesi (83yo)
Independent Director
- Tenure: 18.5yrs
- Compensation: US$391.05k
Alan Garber (63yo)
Independent Director
- Tenure: 14.8yrs
- Compensation: US$390.70k
José Baselga (59yo)
Member of Scientific Advisory Board
- Tenure: 12.8yrs
Company Information
Exelixis, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Exelixis, Inc.
- Ticker: EXEL
- Exchange: NasdaqGS
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.010b
- Shares outstanding: 303.85m
- Website: https://www.exelixis.com
Number of Employees
Location
- Exelixis, Inc.
- 1851 Harbor Bay Parkway
- Alameda
- California
- 94502
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EXEL | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 2000 |
| EX9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2000 |
| 0IJO | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 2000 |
Biography
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products includ ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 23:36 |
| End of Day Share Price | 2019/11/20 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.